News articles about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alimera Sciences earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.8100653749486 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
Shares of Alimera Sciences stock traded up $0.02 during trading on Thursday, reaching $0.77. 610 shares of the stock traded hands, compared to its average volume of 266,847. The firm has a market cap of $54.15 million, a price-to-earnings ratio of -2.66 and a beta of 1.71. The company has a quick ratio of 4.64, a current ratio of 4.81 and a debt-to-equity ratio of -0.62. Alimera Sciences has a 52-week low of $0.74 and a 52-week high of $1.65.
Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.07). The firm had revenue of $9.14 million during the quarter, compared to analysts’ expectations of $9.60 million. equities analysts expect that Alimera Sciences will post -0.3 EPS for the current fiscal year.
A number of brokerages have issued reports on ALIM. ValuEngine upgraded Alimera Sciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Zacks Investment Research lowered Alimera Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, April 25th. Finally, HC Wainwright set a $3.00 price target on Alimera Sciences and gave the stock a “buy” rating in a research note on Tuesday, May 8th.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.